Stability study of capecitabine active pharmaceutical ingredient in bulk drug and pharmaceutical formulation

Journal of Liquid Chromatography and Related Technologies

Volumn 35, Issue 1, 2012, Pages 40-49

  Pujeri, S S ^a   Khader, A M A ^a   Seetharamappa, J ^b  

^a MANGALORE UNIVERSITY   (India)

^b KARNATAK UNIVERSITY   (India)

Author keywords

capecitabine; formulation; impurity; LC MS MS; reverse phase; stability study

Indexed keywords

CAPECITABINE; FORMULATION; LC-MS-MS; REVERSE PHASE; STABILITY STUDY;

ACETONITRILE; AMMONIUM COMPOUNDS; DRUG DOSAGE; DRUG PRODUCTS; FORMIC ACID; IMPURITIES;

PHASE STABILITY;

4 AMINO 1 (3,4 DIHYDROXY 5 METHYLTETRAHYDROFURAN 2 YL) 5 FLUOROPYRIMIDIN 2(1H) ONE; CAPECITABINE; FLUORINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TETRAHYDROFURAN DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG IMPURITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; TABLET FORMULATION;

EID: 84856838087     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826076.2011.593386     Document Type: Article

References (19)

1. Adjei, A. A. Pharmacology and Clinical Status of Capecitabine. Br. J. Clin. Pharmacol. 1999, 48, 265-277.
2. Zufia, L.; Aldaz, A.; Giradles, J. Simple Determination of Capecitabine and Its Metabolites by Liquid Chromatography with Ultraviolet Detection in a Single Injection. J. Chromatogr. B. 2004, 809, 51-58. (Pubitemid 38998419)
3. Diasio, R. Improving Fluorouracil Chemotherapy with Novel Orally Administered Fluoropyrimidines. Drugs. 1999, 58 (3), 119-126. (Pubitemid 30192623)
4. Jansman, F. G. A.; Postma, M. J.; Hartskamp, D. V.; Willemse, P. H. B.; Brouwers, J. R. B. J. Cost-Benefit Analysis of Capecitabine versus 5-Fluorouracil=Leucovorin in the Treatment of Colorectal Cancer in the Netherlands. Clin. Ther. 2004, 26, 579-589. (Pubitemid 38586459)
5. Reigner, B.; Verweij, J.; Dirix, L.; Cassidy, J.; Twelves, C.; Allman, D.; Weidekamm, E.; Roos, B.; Banken, L.; Utoh, M.; Osterwalder, B. Effect of Food on the Pharmacokinetics of Capecitabine and Its Metabolites Following Oral Administration in Cancer Patients. Clin. Cancer Res. 1998, 4, 941-948. (Pubitemid 28183395)
6. Scheithauer, W.; McKendrick, J.; Begbie, S.; Borner, M.; Burns, W. I.; Burris, H. A.; Cassidy, J.; Jodrell, D.; Koralewski, P.; Levine, E. L.; Marschner, N.; Maroun, J.; Garcia- Alfonso, P.; Tujakowski, J.; Van Hazel, G.; Wong, A.; Zaluski, J.; Twelves, C. Oral Capecitabine as an Alternative to i.v. 5-Fluorouracil-Based Adjuvant Therapy for Colon Cancer: Safety Results of A Randomized Phase III Trial. Ann. Oncol. 2003, 14, 1735-1743. (Pubitemid 38029045)
7. Scheithauer, W.; Kornek, G. V.; Raderer, M.; Schull, B.; Schmid, K.; Kovats, E.; Schneeweiss, B.; Lang, F.; Lenauer, A.; Depisch, D. Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal cancer. J. Clin. Oncol. 2003, 21, 1307-1312. (Pubitemid 46606408)
8. Guichard, S. M.; Mayer, I.; Jodrell, D. I. Simultaneous Determination of Capecitabine and Its Metabolites by HPLC and Mass Spectrometry for Preclinical and Clinical Studies. J. Chromatogr. B. 2005, 826, 232-237. (Pubitemid 41446455)
9. Dhananjeyan, M. R.; Liu, J.; Bykowski, C.; Trendel, J. A.; Sarver, J. G.; Ando, H.; Erhardt, P. W. Rapid and Simultaneous Determination of Capecitabine and its Metabolites in Mouse Plasma, Mouse Serum, and in Rabbit bile by HPLC. J. Chromatogr. A. 2007, 1138, 101-108. (Pubitemid 44908341)
10. Yan, X. U.; Grem, J. L. Liquid Chromatography-Mass Spectrometry Method for the Analysis of the Anti-Cancer Agent Capecitabine and Its Nucleoside Metabolites in Human Plasma. J. Chromatogr. B. 2003, 783, 273-285. (Pubitemid 35351655)
11. Salvador, A.; Millerioux, L.; Renou, A. Simultaneous LC-MS-MS Analysis of Capecitabine and its metabolites (5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil) After Off-Line SPE from Human Plasma. Chromatographia 2006, 63, 609-615. (Pubitemid 43893017)
12. Desmoulin, F.; Gilard, V.; Martino, R.; Malet-Martino, M. Isolation of an Unknown Metabolite of Capecitabine, an Oral 5-fluorouracil Prodrug, and Its Identification by Nuclear Magnetic Resonance and Liquid Chromatography-Tandem Mass Spectrometry as a Glucuroconjugate of 5′-deoxy-5-fluorocytidine, Namely 2′-(β-D-glucuronic acid)-50-deoxy-5-fluorocytidine. J. Chromatogr. B. 2003, 792, 323-332. (Pubitemid 36830882)
13. Martino, R.; Gilard, V.; Desmoulin, F.; Malet-Martino, M. Fluorine-19 or Phosphorus-31 NMR Spectroscopy: A Suitable Analytical Technique for Quantitative in vitro Metabolic Studies of Fluorinated or Phosphorylated Drugs. J. Pharm. Biomed. Anal. 2005, 38, 871-891. (Pubitemid 41115794)
14. Malet-Martino, M.; Gilard, V.; Desmoulin, F.; Martino, R. Fluorine Nuclear Magnetic Resonance Spectroscopy of Human Biofluids in the Field of Metabolic Studies of Anticancer and Antifungal Fluoropyrimidine Drugs. Clin. Chim. Acta 2006, 366, 61-73. (Pubitemid 43330967)
15. Hiriyanna, S. G.; Basavaiah, K. Impurity Profile Study of Capecitabine. Acta Chromatographica. 2008, 20, 609-624.
16. Constantinescu, D.; Curea, E. Reversed Phase High Performance Liquid Chromatography (RP-HPLC) Determination of Lisinopril and Its Degradation Products in Stability and Compatibility Studies. Farmacia 2008, 56 (1), 50-56.
17. Csillag, T.; Pocsai, Z.; Bojita, M. Applicability of Chromatographic Method in the Quality Control of Some Pharmaceuticals. Farmacia 2006, 54 (3), 54-61.
18. ICH Topic Q1A (R2); Stability Testing of New Drug Substances and Products, 1999. (CPMP=ICH= 2736=99, http://www.ich.org/LOB/media/MEDIA430.pdf, Accessed January 2011)
19. International Conference on Harmonization; Draft Revised Guidance on Impurities in New Drug Substances. Q3A(R). 2000. Federal Register, 65:45085-45090.